2021 Q4 Form 10-Q Financial Statement
#000095017021003917 Filed on November 10, 2021
Income Statement
Concept | 2021 Q4 | 2021 Q3 | 2020 Q4 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $5.284M | $5.487M | $4.320M |
YoY Change | 22.31% | 38.91% | 49.48% |
% of Gross Profit | |||
Research & Development | $9.214M | $14.81M | $14.62M |
YoY Change | -36.98% | 22.09% | 10.09% |
% of Gross Profit | |||
Depreciation & Amortization | $464.0K | $106.0K | $100.0K |
YoY Change | 364.0% | 17.78% | 25.0% |
% of Gross Profit | |||
Operating Expenses | $14.50M | $14.81M | $18.94M |
YoY Change | -23.45% | 22.09% | 17.13% |
Operating Profit | -$20.30M | ||
YoY Change | 26.26% | ||
Interest Expense | -$2.309M | $2.327M | -$1.140M |
YoY Change | 102.54% | 88.42% | 123.53% |
% of Operating Profit | |||
Other Income/Expense, Net | |||
YoY Change | |||
Pretax Income | -$16.81M | -$22.63M | -$20.08M |
YoY Change | -16.3% | 32.47% | 20.38% |
Income Tax | -$20.00K | ||
% Of Pretax Income | |||
Net Earnings | -$16.81M | -$22.63M | -$20.07M |
YoY Change | -16.26% | 32.49% | 20.4% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$0.86 | ||
Diluted Earnings Per Share | -$635.4K | -$860.1K | -$804.1K |
COMMON SHARES | |||
Basic Shares Outstanding | 26.44M | 26.30M | |
Diluted Shares Outstanding | 26.30M |
Balance Sheet
Concept | 2021 Q4 | 2021 Q3 | 2020 Q4 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $71.22M | $88.71M | $72.80M |
YoY Change | -2.17% | -0.55% | -35.17% |
Cash & Equivalents | $19.86M | $17.63M | $15.87M |
Short-Term Investments | $51.36M | $71.07M | $56.90M |
Other Short-Term Assets | $6.175M | $3.983M | $5.200M |
YoY Change | 18.75% | 24.47% | -1.89% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $77.39M | $92.69M | $77.93M |
YoY Change | -0.69% | 0.42% | -33.72% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $527.0K | $938.0K | $1.023M |
YoY Change | -48.48% | -12.58% | 9.53% |
Goodwill | $881.0K | $881.0K | $881.0K |
YoY Change | 0.0% | 0.0% | 0.0% |
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $1.957M | $1.626M | $1.477M |
YoY Change | 32.5% | 70.08% | 60.89% |
Total Long-Term Assets | $5.919M | $6.077M | $6.169M |
YoY Change | -4.05% | 5.3% | 6.25% |
TOTAL ASSETS | |||
Total Short-Term Assets | $77.39M | $92.69M | $77.93M |
Total Long-Term Assets | $5.919M | $6.077M | $6.169M |
Total Assets | $83.31M | $98.77M | $84.10M |
YoY Change | -0.94% | 0.7% | -31.84% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $5.044M | $7.181M | $5.146M |
YoY Change | -1.98% | 78.94% | 30.44% |
Accrued Expenses | $7.633M | $8.272M | $8.584M |
YoY Change | -11.08% | 32.56% | 57.45% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $12.94M | $15.72M | $13.97M |
YoY Change | -7.4% | 49.75% | 44.09% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $128.1M | $125.8M | $63.40M |
YoY Change | 101.99% | 102.5% | 46.42% |
Other Long-Term Liabilities | $44.00K | $184.0K | $400.0K |
YoY Change | -89.0% | -63.2% | -20.0% |
Total Long-Term Liabilities | $128.1M | $125.9M | $63.80M |
YoY Change | 100.79% | 101.17% | 45.66% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $12.94M | $15.72M | $13.97M |
Total Long-Term Liabilities | $128.1M | $125.9M | $63.80M |
Total Liabilities | $141.3M | $141.9M | $77.98M |
YoY Change | 81.22% | 93.37% | 45.03% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$316.1M | -$299.3M | -$235.6M |
YoY Change | 34.19% | 38.89% | 46.0% |
Common Stock | $258.1M | $256.1M | $241.7M |
YoY Change | 6.8% | 6.69% | 4.66% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | -$58.00M | -$43.17M | $6.118M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $83.31M | $98.77M | $84.10M |
YoY Change | -0.94% | 0.7% | -31.84% |
Cashflow Statement
Concept | 2021 Q4 | 2021 Q3 | 2020 Q4 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$16.81M | -$22.63M | -$20.07M |
YoY Change | -16.26% | 32.49% | 20.4% |
Depreciation, Depletion And Amortization | $464.0K | $106.0K | $100.0K |
YoY Change | 364.0% | 17.78% | 25.0% |
Cash From Operating Activities | -$17.45M | -$18.40M | -$16.45M |
YoY Change | 6.05% | 20.37% | 7.73% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$53.00K | -$25.00K | -$50.00K |
YoY Change | 6.0% | -16.67% | |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $19.70M | -$43.02M | $16.90M |
YoY Change | 16.59% | -398.51% | -140.51% |
Cash From Investing Activities | $19.65M | -$43.04M | $16.86M |
YoY Change | 16.55% | -398.69% | -140.33% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 22.00K | 40.61M | 240.0K |
YoY Change | -90.83% | 18360.0% | -99.6% |
NET CHANGE | |||
Cash From Operating Activities | -17.45M | -18.40M | -16.45M |
Cash From Investing Activities | 19.65M | -43.04M | 16.86M |
Cash From Financing Activities | 22.00K | 40.61M | 240.0K |
Net Change In Cash | 2.227M | -20.83M | 650.0K |
YoY Change | 242.62% | 3056.52% | -75.29% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$17.45M | -$18.40M | -$16.45M |
Capital Expenditures | -$53.00K | -$25.00K | -$50.00K |
Free Cash Flow | -$17.39M | -$18.38M | -$16.40M |
YoY Change | 6.05% | 20.2% | 7.82% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
CY2021Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
CY2020Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001563577 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2021-09-30 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Malvern | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
PA | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
19355 | ||
dei |
City Area Code
CityAreaCode
|
610 | ||
dei |
Entity File Number
EntityFileNumber
|
001-39114 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Galera Therapeutics, Inc. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
46-1454898 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
2 W. Liberty Blvd #100 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
CY2021Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
26438767 | |
CY2021Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
17632000 | |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
15872000 | |
CY2021Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
71073000 | |
CY2020Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
56904000 | |
dei |
Local Phone Number
LocalPhoneNumber
|
725-1500 | ||
dei |
Security12b Title
Security12bTitle
|
Common Stock,$0.001 par value per share | ||
dei |
Trading Symbol
TradingSymbol
|
GRTX | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
true | ||
dei |
Entity Ex Transition Period
EntityExTransitionPeriod
|
true | ||
CY2021Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
3983000 | |
CY2020Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
5153000 | |
CY2021Q3 | us-gaap |
Assets Current
AssetsCurrent
|
92688000 | |
CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
77929000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
938000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1023000 | |
CY2021Q3 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
2258000 | |
CY2020Q4 | us-gaap |
Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
|
2258000 | |
CY2021Q3 | us-gaap |
Goodwill
Goodwill
|
881000 | |
CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
881000 | |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
374000 | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
530000 | |
CY2021Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1626000 | |
CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
1477000 | |
CY2021Q3 | us-gaap |
Assets
Assets
|
98765000 | |
CY2020Q4 | us-gaap |
Assets
Assets
|
84098000 | |
CY2021Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7181000 | |
CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5146000 | |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8272000 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8584000 | |
CY2021Q3 | us-gaap |
Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
|
271000 | |
CY2020Q4 | us-gaap |
Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
|
238000 | |
CY2021Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
15724000 | |
CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
13968000 | |
CY2021Q3 | us-gaap |
Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
|
125751000 | |
CY2020Q4 | us-gaap |
Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
|
63369000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
110000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
296000 | |
CY2021Q3 | us-gaap |
Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
|
273000 | |
CY2020Q4 | us-gaap |
Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
|
273000 | |
CY2021Q3 | us-gaap |
Other Liabilities
OtherLiabilities
|
74000 | |
CY2020Q4 | us-gaap |
Other Liabilities
OtherLiabilities
|
74000 | |
CY2021Q3 | us-gaap |
Liabilities
Liabilities
|
141932000 | |
CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
77980000 | |
CY2021Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
us-gaap |
Interest Expense
InterestExpense
|
3625000 | ||
CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
25000 | |
CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
24976142 | |
CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
24976142 | |
CY2021Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
26000 | |
CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
CY2021Q3 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2020Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
CY2021Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2021Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
CY2021Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
26438767 | |
CY2021Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
26438767 | |
CY2021Q3 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
256104000 | |
CY2020Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
241649000 | |
CY2021Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2000 | |
CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
12000 | |
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-299295000 | |
CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-235568000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-43167000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6118000 | |
CY2021Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
98765000 | |
CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
84098000 | |
CY2021Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14813000 | |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12133000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
43203000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
40225000 | ||
CY2021Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5487000 | |
CY2020Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3945000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
15667000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
11384000 | ||
CY2021Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20300000 | |
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16078000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-58870000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-51609000 | ||
CY2021Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3000 | |
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
235000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
28000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1055000 | ||
CY2021Q3 | us-gaap |
Interest Expense
InterestExpense
|
2327000 | |
CY2020Q3 | us-gaap |
Interest Expense
InterestExpense
|
1235000 | |
us-gaap |
Interest Expense
InterestExpense
|
4882000 | ||
CY2021Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-5000 | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-193000 | |
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-14000 | ||
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
85000 | ||
CY2021Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-22631000 | |
CY2020Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17271000 | |
CY2021Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-2000 | |
us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
-3000 | ||
us-gaap |
Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
|
27000 | ||
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22626000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17078000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-63727000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-54152000 | ||
CY2021Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.86 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.69 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.49 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-2.18 | ||
CY2021Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26304920 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24874805 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25569545 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
24840822 | ||
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22626000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17078000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-63727000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-54152000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-63741000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-54067000 | ||
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
6118000 | |
CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1791000 | |
CY2021Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
235000 | |
CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-2000 | |
CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18715000 | |
CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-10573000 | |
CY2021Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1611000 | |
CY2021Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
120000 | |
CY2021Q2 | grtx |
Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
|
-5718000 | |
CY2021Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-7000 | |
CY2021Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22386000 | |
CY2021Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-25517000 | |
CY2021Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1870000 | |
CY2021Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
890000 | |
CY2021Q3 | grtx |
Sale Of Shares Under Open Market Sale Agrrement
SaleOfSharesUnderOpenMarketSaleAgrrement
|
-2221000 | |
CY2021Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-5000 | |
CY2021Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-22626000 | |
CY2021Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-43167000 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
69608000 | |
CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1210000 | |
CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
9000 | |
CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
648000 | |
CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18417000 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
53058000 | |
CY2020Q2 | grtx |
Issuance Of Common Stock Warrants
IssuanceOfCommonStockWarrants
|
4712000 | |
CY2020Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1453000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
41000 | |
CY2020Q2 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-370000 | |
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18657000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
40237000 | |
CY2020Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1505000 | |
CY2020Q3 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
224000 | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-193000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17078000 | |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
24695000 | |
us-gaap |
Profit Loss
ProfitLoss
|
-63727000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-54152000 | ||
us-gaap |
Depreciation
Depreciation
|
314000 | ||
us-gaap |
Depreciation
Depreciation
|
272000 | ||
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
4882000 | ||
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
3625000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5272000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4168000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1171000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-2089000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-7000 | ||
us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-212000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
2035000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
68000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-466000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
631000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-50512000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-43087000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
67183000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
53650000 | ||
us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
53000000 | ||
us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
73750000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
230000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
411000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-14413000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
19689000 | ||
grtx |
Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
|
57500000 | ||
grtx |
Proceeds From Royalty Purchase Agreement
ProceedsFromRoyaltyPurchaseAgreement
|
20000000 | ||
grtx |
Proceeds From Open Market Sale Agreement
ProceedsFromOpenMarketSaleAgreement
|
7939000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
1246000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
274000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
66685000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
20274000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
1760000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-3124000 | ||
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
15872000 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
18356000 | |
CY2021Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
17632000 | |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
15232000 | |
grtx |
Issuance Of Warrants In Conjunction With Amendment To The Royalty Purchase Agreement
IssuanceOfWarrantsInConjunctionWithAmendmentToTheRoyaltyPurchaseAgreement
|
4712000 | ||
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
7000 | ||
dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2012-11-19 | ||
CY2021Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-299300000 | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of unaudited interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, royalty purchase liability assumptions and accrued research and development expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p> | ||
grtx |
Increase Decrease In Research And Development Expense
IncreaseDecreaseInResearchAndDevelopmentExpense
|
300000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5333390 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5026128 | ||
grtx |
Covid Nineteen Update Policy Textblock
CovidNineteenUpdatePolicyTextblock
|
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 update</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and related precautions have directly or indirectly impacted the timeline for some of the Company’s clinical trials. In April 2020, the Company delayed the initiation of the Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, or EUSOM trial, due to concerns with patient enrollment. The first patient was dosed in this trial in June 2020, and target enrollment was decreased to approximately 35 patients due to the delay. This trial was expected to contribute to the safety database for avasopasem in patients with HNC receiving radiotherapy. As a result of the delay in initiating the trial in Europe, the target enrollment for the ROMAN trial was increased to approximately 450 patients to ensure the Company was positioned to maintain the overall planned size of the safety database in a timely manner. The Company reported topline data from the ROMAN trial in October 2021 and expects to report topline data from the EUSOM trial in the fourth quarter of 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company initiated a pilot Phase 2 clinical trial of avasopasem to evaluate its ability to improve 28-day mortality in hospitalized patients who are critically ill with COVID-19. The trial aimed to enroll up to 50 hospitalized adult patients critically ill with COVID-19 at several sites across the U.S. On June 16, 2021, the Company ceased enrolling subjects in this trial. Enrollment in the trial was limited at the three centers that participated. Due to the overall decline in COVID-related hospitalizations in the U.S. at the time, the Company determined that it was not feasible to complete the trial.</span></p> | ||
us-gaap |
Fair Value Liabilities Measured On Recurring Basis Debt Instrument Valuation Techniques Change In Technique Quantification Of Effect
FairValueLiabilitiesMeasuredOnRecurringBasisDebtInstrumentValuationTechniquesChangeInTechniqueQuantificationOfEffect
|
0 | ||
CY2021Q3 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2061000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1832000 | |
CY2021Q3 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1123000 | |
CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
809000 | |
CY2021Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
938000 | |
CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1023000 | |
us-gaap |
Depreciation
Depreciation
|
300000 | ||
us-gaap |
Depreciation
Depreciation
|
300000 | ||
CY2021Q3 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
1984000 | |
CY2020Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
2632000 | |
CY2021Q3 | grtx |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5986000 | |
CY2020Q4 | grtx |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5525000 | |
CY2021Q3 | grtx |
Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
|
302000 | |
CY2020Q4 | grtx |
Accrued Professional Fees And Other Expenses Current
AccruedProfessionalFeesAndOtherExpensesCurrent
|
427000 | |
CY2021Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8272000 | |
CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8584000 | |
CY2021Q3 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P6Y | |
CY2021Q3 | us-gaap |
Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
|
4700000 | |
CY2021Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
374000 | |
CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
530000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
271000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
238000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
110000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
296000 | |
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
381000 | |
CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
534000 | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
252000 | ||
CY2021Q3 | grtx |
Operating Lease Interest Expense
OperatingLeaseInterestExpense
|
5000 | |
CY2020Q3 | grtx |
Operating Lease Interest Expense
OperatingLeaseInterestExpense
|
8000 | |
grtx |
Operating Lease Interest Expense
OperatingLeaseInterestExpense
|
18000 | ||
grtx |
Operating Lease Interest Expense
OperatingLeaseInterestExpense
|
27000 | ||
CY2021Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
81000 | |
CY2020Q3 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
84000 | |
us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
243000 | ||
CY2021Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
76000 | |
CY2020Q3 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
76000 | |
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
225000 | ||
us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
225000 | ||
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
245000 | ||
us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
344000 | ||
us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
70000 | ||
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
83000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
266000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
44000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
393000 | |
CY2021Q3 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
12000 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3M18D | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2599164 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
6.36 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y | ||
CY2021Q3 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
381000 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
4782729 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4782729 | |
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.59 | |
CY2021Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1870000 | |
CY2020Q3 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1505000 | |
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
5272000 | ||
us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4168000 | ||
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4463078 | |
CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.40 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1318852 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
11.07 | ||
us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
571257 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.18 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
427944 | ||
us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
12.40 | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
8.59 | |
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P7Y3M18D | ||
CY2021Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
17600000 | |
us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y8M12D | ||
CY2021Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
8400000 | |
CY2021Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
8100000 | |
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
8.26 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
10.45 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y2M12D | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y2M12D | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.904 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.893 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0069 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.0126 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 |